Neurol. pro Praxi, 2005; 5: 264-266

Sclerosis multiplex a autoimunitné ochorenia

doc. MUDr. Eleonóra Klímová CSc

V súčasnosti možno sledovať v krajinách severného a stredného zemepisného pásma stúpajúcu incidenciu sclerosis multiplex (SM), ale aj ďalších autoimunitných ochorení (AIO), ktoré sa klinicky prejavia vo včasnej dospelosti, resp. v strednom veku. SM je považovaná za príklad autoimunitného ochorenia CNS. Jej predpokladaná etiopatogenéza i povaha autoimunitnej poruchy dovoľujú súčasný výskyt (komorbiditu) s inými AIO. Práve táto problematika je v poslednom čase v centre pozornosti epidemiologických a imunologických štúdií, s cieľom ozrejmiť molekulové a bunkové základy vzniku ochorenia. Nemenej významné je aj zistenie miery rizika vzniku AIO u pacientov so SM a stanovenie ich vplyvu na samotný priebeh choroby. Je preto nesmierne dôležité v každodennej praxi myslieť na tieto súvislosti.

Keywords: Kľúčové slová: sclerosis multiplex, autoimunitné ochorenia, komorbidita.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klímová E. Sclerosis multiplex a autoimunitné ochorenia. Neurol. praxi. 2005;6(5):264-266.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bárová H. Imunitní děje v patogenezi diabetes mellitus 1. typu. In: Perušičová J, ed. Trendy soudobé diabetologie. Galén Praha; 2002: 101.
    2. Bartůňková J. Imunodeficience. Grada Publishing Praha; 2002: 21.
    3. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DAS. Autoimmune disease in first - degree relatives of patient with multiple sclerosis. Brain 2000; 123: 1102-1111. Go to original source... Go to PubMed...
    4. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003; 2 (3): 119-25. Go to original source... Go to PubMed...
    5. Donadio V, Corteli P, Liguori R, Di Stasi V, Montagna P. Multiple sclerosis - like disease in polyglandular autoimmune syndrom. J Neurol 2001; 248 (1): 61-62. Go to original source... Go to PubMed...
    6. Dönmez B, Özakbas S, Öktem MA, Gedizlioglu M, Coker I, Genc A, et al. HLA genotypes in turkish patients with myasthenia gravis: Comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features. Hum Immunol 2004; 65 (7): 752-757. Go to original source... Go to PubMed...
    7. Drobný M. Úvod do problematiky, prehľad súčasných názorov, história vývoja poznania, vyhliadky do budúcnosti. In: Drobný M et al. Sclerosis multiplex. Reklas Martin; 2002: 8-26.
    8. Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E. et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002; 249: 1088-1097. Go to original source... Go to PubMed...
    9. Havrdová E. Roztroušená skleróza mozkomíšní. In: Havrdová E et al. Neuroimunologie. Maxdorf Praha; 2002: 231.
    10. Henderson RD, Bain ChJ, Pender MP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000; 7 (5): 434-437. Go to original source... Go to PubMed...
    11. Lassmann H. Pathology of multiple sclerosis. In: McAlpine's Multiple Sclerosis. 3. vyd; Churchil Livingstone Londyn; 1999: 323-358. Go to original source...
    12. Markovic M, Trajkovic V, Drulovic J, Mesaros S, Stojsavljevic N, Dujmovic I, et al. Antibodies against myelin oligodendrocyte glykoprotein in the cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 2003; 211(1-2): 67-73. Go to original source... Go to PubMed...
    13. Modern Management Workshop, San Francisco 2003. Early Management of Multiple sclerosis. In: MS Forum, Parexel Cambridge 2004; 45-51.
    14. Piťha J. Myasthenia gravis. In: Havrdová E et al. Neuroimunologie. Maxdorf Praha; 2002: 284-287.
    15. Tremlett H, Lee C, Ho K, Devonshire V. Prevalence of diabetes and asthma in a multiple sclerosis clinic population, British Columbia, Canada. Multiple Sclerosis 2004; 10 (suppl. 2): Abstract, s. 98-99.
    16. Van der Aa A, Hellings N, Bernard CC, Raus J, Stinissen P. Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls. J Neuroimmunol 2003; 137 (1-2): 164-176. Go to original source... Go to PubMed...
    17. Wekerle H. Immunology of multiple sclerosis. In: McAlpine's Multiple Sclerosis. 3. vyd., Churchil Livingstone Londýn; 1999: 379.
    18. Winer S, Astsaturov I, Cheung RK, Gunaratnam L, Kubiak V, Cortez MA, et al. Type 1 diabetes and multiple scerosis patients target islets plus central nervous system autoantigens., Nonimmunised nonobese diabetic mice can develop autoimmune encephalitis, J Immunol 2001, 166 (4): 2831-2841. Go to original source... Go to PubMed...
    19. Winer S, Astsaturov I, Cheung RK, Schrade K, Gunaratnam L, Wood DD, et al. T cells of multiple sclerosis patients target a common enviromental peptide that causes encephalitis in mice. J Immunol 2001, 166 (7): 4751-4756. Go to original source... Go to PubMed...
    20. Winer S, Tsui H, Lau A, Song A, Li X, Cheung RK, et al. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med 2003, 9 (2): 198-205. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.